Regulatory filing 📈 Stocks 🌍 United States

MetaVia Reports Positive Preclinical Data for DA-1726 vs. Retatrutide

MetaVia's DA-1726 matched retatrutide's weight loss in preclinical mouse models while demonstrating greater glucose control and reduced appetite suppression, bolstering plans for a 2027 Phase 2 trial.

🕐 1 min read

1 assets impacted (Stocks). Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: MTVA ↑ 4/10 (55% confidence).

📊 Affected Assets (1)

MTVA
Bullish 🤖 55%
📅 Short-term 🌍 US · Explicit

Head-to-head preclinical data presented on November 14, 2026 at ObesityWeek 2026 showed DA-1726 matched retatrutide's weight loss (41.7% vs 43.6% high dose) with greater glucose lowering (43.0% vs 32.5%) and significantly increased hepatic FGF21 (p<0.001), supporting the liver-disease focus. For a clinical-stage biotech this is a supportive datapoint, but it is mouse data and the Phase 2 study in MetALD and ALD is not targeted until the second half of 2027, which limits the near-term re-rating.

Catalysts
  • ▲ Positive head-to-head preclinical data vs retatrutide presented November 14, 2026 at ObesityWeek 2026
  • ▲ Phase 2, 48-week study of DA-1726 in MetALD and ALD planned to begin in the second half of 2027
Risk Factors
  • ▼ All new data are preclinical, from diet-induced obese mice over roughly three weeks, not from humans
  • ▼ Confirmatory efficacy is only planned for a Phase 2 study starting in the second half of 2027

🧭 Full analysis of these assets

🎯 Key Takeaways

  • DA-1726 achieved 41.7% weight loss in high-dose mice, comparable to 43.6% for retatrutide.
  • Plasma glucose levels dropped by 43.0% with DA-1726 compared to 32.5% for retatrutide at high doses.
  • DA-1726 showed significantly increased hepatic FGF21 expression (p<0.001) in preclinical testing.
  • Phase 2 study for DA-1726 in MetALD and ALD is targeted to begin in the second half of 2027.

📝 Executive Summary

MetaVia Inc. presented preclinical data at ObesityWeek 2026 showing its dual-agonist DA-1726 achieved weight loss comparable to retatrutide in mice, with 41.7% reduction at high doses. The study highlighted superior glucose lowering and increased hepatic FGF21 expression, supporting the company's focus on liver-related cardiometabolic diseases. MetaVia plans to initiate a Phase 2 study for MetALD and ALD in the second half of 2027.

❓ FAQ

How good were the results compared with the competitor drug?

In obese mice, DA-1726 cut body weight by 41.7% at the high dose versus 43.6% for retatrutide, lowered plasma glucose by 43.0% versus 32.5%, and significantly raised liver and circulating FGF21, while suppressing food intake far less (31.2% versus 41.4%).

When will human data follow?

MetaVia is preparing a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD targeted to begin in the second half of 2027; prior Phase 1 interim data showed a 13.5% placebo-adjusted weight reduction and a 68.0% liver-fat reduction at Day 109.